Venezuelan Equine Encephalitis Virus

Findings Will Help in Developing Safer Vaccine

Published in Medical Letter on the CDC and FDA, January 31st, 2000

Researchers from England reported research findings that will aid the understanding of the appropriate immune response profile against airborne Venezuelan equine encephalitis virus.

The live-attenuated vaccine (TC-83) for Venezuelan equine encephalitis (VEE) virus is known to protect against subcutaneous and airborne infection, noted S. J. Elvin and colleagues.

Elvin et al. reported that the optimal dose of vaccine required to protect Balb/c mice against aerosol infection with virulent VEE was defined, and the immunological parameters were measured in protected mice.

The researchers presented their study, titled "Immune response...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-01-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry